Corporate | 25 November 2014 12:07
|
HAEMATO AG / Key word(s): 9-month figures/Quarter Results
Corporate News of HAEMATO AG: Business performance in the first 9 months 2014 In the first 9 months 2014 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS Group sales of EUR 156.37 million (Prior-year period: EUR 118.30 million) and net profit for the period of EUR 6.60 million (Prior-year period: EUR 6.15 million). “By introducing botulinum preparations and hyaluronic acid we are now developing our business in the strong growing lifestyle segment within the healthcare market. We will continue to expand our range of products to participate in the growth of this attractive market segment. For the whole of 2014, we are still aiming for annual revenue of more than EUR 200 million. Based on this assessment of the business development we can reconfirm the established dividend policy for 2014″, says Dr. Christian Pahl, Member of the Management Board of HAEMATO AG. About HAEMATO: HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of the business activities lies on the growth markets of patent free and patent protected medicinal products. Focal points are therapies with cancer, HIV and other chronic diseases. The company is listed on the Frankfurt Stock Exchange in the Entry Standard (Open Market).
Key figures for the share of HAEMATO AG:
HAEMATO AG, Investor Relations Telefon: +49 (0)30 897 30 86 70 ir@haemato.de 25.11.2014 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
| 299225 25.11.2014 |